ImagenBio Adopts 2025 Equity Inducement Plan to Retain Top Talent

ImagenBio, Inc. has adopted the 2025 Equity Inducement Plan to attract and retain employees, providing incentives for maximum effort and an opportunity to benefit from increases in common stock value. The plan allows for non-statutory stock options and restricted stock unit awards in accordance with Nasdaq Listing Rule 5635(c)(4). The plan will come into existence on the adoption date, but no award can be granted prior to the effective date. The share reserve may be adjusted to reflect changes in the Company's capital structure.

ImageneBio, Inc. (Nasdaq: IMA), a clinical-stage biotechnology company focused on immunological and inflammatory diseases, has adopted the 2025 Equity Inducement Plan to attract and retain talent. The plan, which will come into existence on the adoption date, allows for non-statutory stock options and restricted stock unit awards in accordance with Nasdaq Listing Rule 5635(c)(4) [2].

The plan aims to incentivize maximum effort from employees by providing them with an opportunity to benefit from increases in the company's common stock value. It is designed to align the interests of employees with those of the company's shareholders.

Key features of the 2025 Equity Inducement Plan include:
- Non-statutory stock options and restricted stock unit awards.
- Vesting schedules that provide employees with a mix of immediate and long-term benefits.
- A share reserve that can be adjusted to reflect changes in the company's capital structure.

The plan was adopted to address the company's need to attract and retain top talent in the competitive biotechnology industry. By offering employees the opportunity to participate in the company's equity, ImageneBio aims to foster a culture of ownership and commitment.

The adoption of the 2025 Equity Inducement Plan follows the company's recent appointment of Dr. Kristin Yarema as its Chief Executive Officer. As part of her compensation package, Dr. Yarema was granted 436,080 stock options and 153,505 restricted stock units (RSUs) [2].

The plan is subject to the terms and conditions of ImageneBio's 2025 Inducement Plan and the applicable award agreements. All awards are contingent on Dr. Yarema's continued service with the company.

ImageneBio's adoption of the 2025 Equity Inducement Plan is a significant step in its efforts to build a strong, motivated workforce and drive its mission to develop treatments for immunological/autoimmune and inflammatory (I&I) diseases.

References:
[1] https://www.stocktitan.net/news/IMA/imagene-bio-reports-inducement-grants-under-nasdaq-listing-rule-5635-tj0tooplec6q.html
[2] https://www.morningstar.com/news/business-wire/20250801242152/cardlytics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4